Profiling of epigenetic features in clinical samples reveals novel widespread changes in cancer

Aberrations in histone post-translational modifications (PTMs), as well as in the histone modifying enzymes (HMEs) that catalyze their deposition and removal, have been reported in many tumors, and many epigenetic inhibitors are currently under investigation for cancer treatment. Therefore, profiling epigenetic features in cancer could have important implications for the discovery of both biomarkers for patient stratification and novel epigenetic targets. In this study, we employed mass spectrometry based approaches to comprehensively profile histone H3 PTMs in a panel of normal and tumoral tissues for different cancer models